Heart Failure is a chronic condition in which the heart doesn’t pump blood as well as it should.
One of the main causes of heart failure is the amyloidosis disease (“Alzheimer’s of the heart”), protein accumulation in between the heart muscle cells, disrupting the heart’s activity.
For many years, cardiac amyloidosis, like Alzheimer’s’, has been considered an incurable disease.
Recently, for the first time, a drug that partially slows down the heart injury process was approved by the U.S. Food and Drug Administration (FDA), but the road to healing is still long.
Kaplan Medical Center’s researchers, however, have developed the innovative drug that has the full healing potential of the disease.
Their study, including successful animal experiments, was published in the European Heart Journal.
The new drug is an antibody that activates the immune system cells in the heart, so they will swallow and break down the amyloid protein that accumulates in the heart.
This way, thus the cardiac muscle cells are protected and return to normal functioning.
The next step, according to the researchers, is to apply these findings to the treatment of heart failure patients with amyloidosis background. (Xinhua/NAN)